56709-70-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 3-bromo-5-methoxybenzoate is utilized as a key intermediate in the production of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of complex molecules that can target specific biological pathways.
Used in Agrochemical Production:
In the agrochemical industry, ethyl 3-bromo-5-methoxybenzoate serves as an essential component in the synthesis of pesticides and other crop protection agents, enhancing agricultural productivity and crop protection.
Used in Organic Chemistry Research:
Ethyl 3-bromo-5-methoxybenzoate is employed as a building block in organic chemistry for the preparation of complex organic molecules. Its versatile chemical properties make it a valuable tool for researchers in the development of novel chemical reactions and synthesis strategies.
Used in Medicinal Chemistry:
Due to its potential biological activities, ethyl 3-bromo-5-methoxybenzoate is explored in medicinal chemistry for its implications in the discovery and design of new pharmaceutical compounds with therapeutic potential.
Used in Scientific Research and Development:
ethyl 3-bromo-5-methoxybenzoate's chemical reactivity and properties have made it a valuable asset in scientific research and development, where it is studied to understand and innovate in various areas of chemistry and related fields.

InChI:InChI=1/C10H11BrO3/c1-3-14-10(12)7-4-8(11)6-9(5-7)13-2/h4-6H,3H2,1-2H3

Upstream product

• 67-56-1 methanol 
• 157893-14-6 3-bromo-5-methoxybenzoic acid 
• 201230-82-2 carbon monoxide 
• 74137-36-3 3,5-dibromoanisole 
• 618-58-6 3,5-dibromobenzoic acid 
• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 192810-12-1 3-bromo-5-hydroxy-benzoic acid methyl ester 
• 74-88-4 methyl iodide 
• 762292-57-9 4-amino-3-bromo-5-methoxy-benzoic acid methyl ester 
• 186581-53-3 diazomethane 

Downstream Products

• 1186519-10-7 methyl 3-methoxy-5-(5-methylpyridin-2-yl)benzoate 
• 1427408-19-2 3-(3-fluorophenyl)-N-(3-hydroxy-2,6-dimethylphenyl)-5-methoxybenzamide 
• 1427408-20-5 3-[[3-(3-fluorophenyl)-5-methoxyphenyl]methylamino]-2,4-dimethylphenol 
• 1427408-21-6 C₂₇H₃₀FNO₄ 
• 1427408-22-7 C₂₆H₂₈FNO₄ 
• 1427406-54-9 C₂₃H₂₂FNO₄ 
• 1427406-55-0 C₂₄H₂₄FNO₄ 
• 1214369-81-9 5-methoxybiphenyl-3-carboxylic acid 
• 916343-77-6 3-cyclopropyl-5-methoxy-benzoic acid methyl ester 
• 23523-94-6 1-methoxy-3-methoxycarbonyl-9H-carbazole 
• 4532-33-6 1-methoxy-3-methylcarbazole 
• 723-97-7 murrayanine 
• 3889-89-2 mukoeic acid 
• 889654-06-2 3-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzoic acid methyl ester 

Relevant academic research and scientific papers

Total synthesis of carbazole alkaloids

A Suzuki-Miyaura cross coupling, followed by triphenylphosphine mediated Cadogan reductive cyclization sequence provided efficient access to a series of carbazole alkaloids. In the present work, this approach was applied to the total synthesis of mukonine, clauszoline K, koenoline, murrayanine, murrayafoline A, mukoeic acid, glycoborine, glycozolicine, mukolidine, mukoline, glycozoline, 3-methoxy-9H-carbazole-1-carboxylic acid methyl ester, (3-methoxy-9H-carbazol-1-yl)-methanol, 3-methoxy-9H-carbazole-1-carbaldehyde, 3-methoxy-9H-carbazole-1-carboxylic acid, 2-methyl-9H-carbazole and nonsteroidal anti-inflammatory drug (NSAID) carprofen and its derivatives.

Development of inhibitors against mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches

Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The present invention discloses compounds according to Formula (I): wherein R1, R2, R3, R4, L, and X are as defined herein. The present invention relates to compounds,methods for their production, pharmaceutical

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The present invention discloses compounds according to Formula I: wherein R1, R2, R3, R4, L, and X are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical

NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF

Provided are novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of F

NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE

The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R1, R2, R3, R4, R5, X, Y and G are as defined in the description, to pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of FGFR, for example, cancer.

ANILINE DERIVATIVES,THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to aniline derivatives, to their preparation and to their therapeutic application.

Discovery of dap-3 polymyxin analogues for the treatment of multidrug-resistant gram-negative nosocomial infections

We report novel polymyxin analogues with improved antibacterial in vitro potency against polymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa. In addition, a human renal cell in vitro assay (hRPTEC) was used to inform structure-toxicity relationships and further differentiate analogues. Replacement of the Dab-3 residue with a Dap-3 in combination with a relatively polar 6-oxo-1-phenyl-1,6-dihydropyridine-3- carbonyl side chain as a fatty acyl replacement yielded analogue 5x, which demonstrated an improved in vitro antimicrobial and renal cytotoxicity profiles relative to polymyxin B (PMB). However, in vivo PK/PD comparison of 5x and PMB in a murine neutropenic thigh model against P. aeruginosa strains with matched MICs showed that 5x was inferior to PMB in vivo, suggesting a lack of improved therapeutic index in spite of apparent in vitro advantages.

TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where X, A?, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated recepto

An efficient synthesis of substituted meta-halophenols and their methyl ethers: insight into the reaction mechanism

An expeditious synthetic methodology leading to substituted meta-halophenols and their corresponding methyl ether derivatives through acid-mediated fragmentation of suitably substituted dihalonorbornyl ketones has been devised. The reaction sequence consi